

would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel: Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21).

Date: January 15, 2025.

Time: 11:30 a.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institute of Environmental Health Sciences, Keystone Building, 530 Davis Drive, Durham, NC 27709.

Meeting Format: Virtual Meeting.

Contact Person: Murali Ganesan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training (DERT), National Institute of Environmental Health Sciences, National Institutes of Health, Keystone Building, Room 3097, Research Triangle Park, NC 27713, Phone: 984-287-4674, Email: murali.ganesan@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: December 12, 2024.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-29836 Filed 12-17-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Early-Stage Dissemination and Implementation Research in Communication Disorders.

Date: January 16, 2025.

Time: 12:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Boulevard, Room 8351, Bethesda, MD 20892, (301) 451-6339, kellya2@nih.gov.

Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Inner Ear Imaging RFA Review.

Date: January 30, 2025.

Time: 1:30 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Contact Person: Kausik Ray, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Blvd., Rockville, MD 20852, 301-402-3587, rayk@nidcd.nih.gov.

Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Institutional Research Training Opportunities Review.

Date: January 31, 2025.

Time: 1:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Boulevard, Room 8351, Bethesda, MD 20892, (301) 451-6339, kellya2@nih.gov.

Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Clinical Research Center Grant (P50) Review.

Date: February 6, 2025.

Time: 1:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Contact Person: Kausik Ray, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Blvd., Rockville, MD 20852, 301-402-3587, rayk@nidcd.nih.gov.

Name of Committee: National Institute on Deafness and Other Communication

Disorders Special Emphasis Panel; Chemosensory Fellowship Review Meeting.

Date: February 11, 2025.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Contact Person: Sonia Elena Nanescu, Ph.D., Scientific Review Officer, Division of Extramural Activities, NIDCD, NIH, 6001 Executive Blvd., Suite 8300, Bethesda, MD 20892, (301) 496-8683, sonia.nanescu@nih.gov.

Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Hearing and Balance Fellowship Review.

Date: February 21, 2025.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: Hilton Garden Inn Seaworld Orlando, FL.

Meeting Format: Virtual Meeting.

Contact Person: Martin Basch, Ph.D., Scientific Review Officer, NIH/NIDCD, Scientific Review Branch, 6001 Executive Blvd., Suite 8300, Bethesda, MD 20892, (301) 496-9693, martin.basch@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS)

Dated: December 12, 2024.

Victoria E. Townsend,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-29910 Filed 12-17-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; HEAL Initiative: Translating Research to Practice to End the Overdose Crisis.

Date: January 23–24, 2025.

Time: 10:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institute of Health
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.

Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
REI: Research at Minority Serving
Institutions on Neurocognitive Mechanisms
Underlying the Impact of Structural Racism
on the Substance Use Trajectory.

Date: February 3, 2025.

Time: 3:00 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant
applications.

Address: National Institute of Health
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shareen Amina Iqbal,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
shareen.iqbal@nih.gov.

Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developing Digital Therapeutics for
Substance Use Disorders.

Date: February 5, 2025.

Time: 1:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant
applications.

Address: National Institute of Health
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shareen Amina Iqbal,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
shareen.iqbal@nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)

Dated: December 12, 2024.

Lauren A. Fleck,

*Program Analyst, Office of Federal Advisory
Committee Policy.*

[FR Doc. 2024–29831 Filed 12–17–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

The National Institutes of Health Public Access Policy

AGENCY: National Institutes of Health,
HHS.

ACTION: Notice.

SUMMARY: The 2024 National Institutes
of Health (NIH) Public Access Policy
implements additional steps to
accelerate free public access to scholarly
publications resulting from the research
that NIH supports, building upon NIH's
long history of providing public access
to research results.

FOR FURTHER INFORMATION CONTACT:

Hilary Leeds, J.D., Senior Policy Analyst
for Public Access, Office of Science
Policy, at (301) 496–9838 or
SciencePolicy@od.nih.gov.

SUPPLEMENTARY INFORMATION:

Background

Increasing access to publications
resulting from the National Institutes of
Health (NIH) funding offers many
benefits to the scientific community and
the public who funded the underlying
research. When patients, families, and
healthcare providers can access
published findings resulting from NIH
funding, they are able to better
understand and address the most
critical health concerns facing their
communities. It also allows researchers,
students, and members of the public in
all communities to have equitable
access to such content. This access can
accelerate future research, lead to
collaboration, and allow interested
readers and patients to follow the latest
advances more closely. Importantly,
these goals reflect NIH's commitment to
the responsible stewardship of the
Nation's investment in biomedical
research by improving transparency and
accessibility of taxpayer-funded
research, an essential component of
fostering trust in research. NIH is
issuing this updated Public Access
Policy to further advance these goals by
accelerating free public access to
research results.

NIH has a long history of providing
access to research products resulting
from its funded research. The NIH
Public Access Policy [https://
sharing.nih.gov/public-access-policy/
public-access-policy-overview](https://sharing.nih.gov/public-access-policy/public-access-policy-overview) in effect
since 2008, requires that NIH-supported
researchers submit their final peer-
reviewed manuscripts to the National
Library of Medicine's PubMed Central®
digital archive of full-text biomedical

and life sciences journal literature upon
acceptance for publication, to be made
freely available to the public after an
allowable embargo period of not more
than 12 months after the official date of
publication. The 2008 Policy
implements Public Law 110–161
[https://www.congress.gov/110/statute/
STATUTE-121/STATUTE-121-
Pg1844.pdf](https://www.congress.gov/110/statute/STATUTE-121/STATUTE-121-Pg1844.pdf), which was made a
legislative mandate for FY 2009 and
beyond by Public Law 111–8 [https://
www.govinfo.gov/content/pkg/PLAW-
111publ8/pdf/PLAW-111publ8.pdf](https://www.govinfo.gov/content/pkg/PLAW-111publ8/pdf/PLAW-111publ8.pdf). The
Policy has, to date, resulted in more
than 1.5 million articles reporting on
NIH-supported research being freely
available to the public in PubMed
Central.

On August 25, 2022, the White House
Office of Science and Technology Policy
(OSTP) released updated policy
guidance (2022 OSTP Memorandum
[https://www.whitehouse.gov/wp-
content/uploads/2022/08/08-2022-
OSTP-Public-Access-Memo.pdf](https://www.whitehouse.gov/wp-content/uploads/2022/08/08-2022-OSTP-Public-Access-Memo.pdf)) to all
federal agencies with research and
development expenditures to further
promote equity, advance trust in
science, and continue to advance
American scientific leadership.
Following the 2022 OSTP
Memorandum, NIH released its Plan to
Enhance Public Access to the Results of
NIH-Supported Research [https://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-23-091.html](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-091.html) in February 2023
(hereafter, the NIH Public Access Plan)
and its Draft Public Access Policy
[https://www.federalregister.gov/
documents/2024/06/18/2024-13373/
request-for-information-on-the-national-
institutes-of-health-draft-public-access-
policy](https://www.federalregister.gov/documents/2024/06/18/2024-13373/request-for-information-on-the-national-institutes-of-health-draft-public-access-policy) in June 2024 (NIH Draft Public
Access Policy). The NIH Public Access
Plan and Draft Public Access Policy
provided a roadmap for how NIH
proposed to accelerate access to
scholarly publications, consistent with
the government-wide expectation to
remove the 12-month embargo period
before public availability. This 2024
NIH Public Access Policy is consistent
with the expectations of the 2022 OSTP
Memorandum regarding scholarly
publications and is informed by all
public feedback, including comments
submitted in response to the NIH Draft
Public Access Policy.

Overview of Public Comments

A total of 144 written public
comments [https://osp.od.nih.gov/wp-
content/uploads/2024/10/Compiled-
Public-Comments-on-RFI-on-the-NIH-
Draft-Public-Access-Policy-508C.pdf](https://osp.od.nih.gov/wp-content/uploads/2024/10/Compiled-Public-Comments-on-RFI-on-the-NIH-Draft-Public-Access-Policy-508C.pdf)
were received in response to the NIH
Draft Public Access Policy. Written
comments were received from a variety